Johnson & Johnson (JNJ) Stock Analysis 2026: Is This Healthcare Giant Still a Buy?

title: "Johnson & Johnson (JNJ) Stock Analysis 2026: Is This Healthcare Giant Still a Buy?" description: "In-depth Johnson & Johnson (JNJ) stock analysis for 2026. We calculate Graham Number, intrinsic value, analyze 64 years of dividend growth, and assess the post-Kenvue J&J." date: "2026-03-05" category: "Stock Analysis" author: "Poor Man's Stocks" image: "/images/blog/jnj-stock-analysis.jpg"

Last updated: March 5, 2026 — All stock data sourced from StockAnalysis.com and Google Finance.

Johnson & Johnson has raised its dividend for 64 consecutive years. Through recessions, pandemics, wars, and litigation crises — the check has arrived every single quarter since 1962.

That is not just a streak. That is an identity.

But J&J in 2026 is a fundamentally different company than it was two years ago. The Kenvue spinoff stripped away the consumer health segment — no more Band-Aid, Tylenol, or Listerine. What remains is a pure-play pharmaceutical and medical devices company. A leaner, more focused operation. And one that just posted $94.2 billion in revenue with a 28% net profit margin.

The question every value investor needs to answer: is the new J&J worth $240 a share?

Let us find out.

Johnson & Johnson at a Glance: Key Metrics (March 2026)

| Metric | Value | |---|---| | Stock Price | $239.63 | | Market Cap | $577.5B | | Revenue (FY 2025) | $94.19B | | Net Income (FY 2025) | $26.80B | | EPS (Diluted) | $11.03 | | P/E Ratio | 21.73 | | Forward P/E | 20.77 | | Dividend Per Share | $5.20 | | Dividend Yield | 2.12% | | Payout Ratio | 47.14% | | Book Value Per Share | $33.57 | | Free Cash Flow (TTM) | $23.06B | | Free Cash Flow Per Share | $9.49 | | Consecutive Dividend Growth Years | 64 | | Beta | 0.33 | | 52-Week Range | $141.50 - $251.71 |

Data sourced from StockAnalysis.com as of March 2026.

The Post-Kenvue J&J: A Completely Different Company

In August 2023, Johnson & Johnson completed the spinoff of Kenvue (KVUE), separating its consumer health business into an independent public company. This was the most significant structural change in J&J's 140-year history.

What J&J kept:

Innovative Medicine (pharmaceuticals): blockbuster drugs like Stelara, Darzalex, Tremfya, and Erleada
MedTech (medical devices): orthopedics, surgical instruments, vision care

What J&J gave away:

Band-Aid, Tylenol, Neutrogena, Listerine, Aveeno — the entire consumer brand portfolio that made J&J a household name

The result? J&J is now a higher-margin, faster-growing company. Pharmaceutical margins crush consumer goods margins. And the numbers show it.

Revenue and Earnings Growth: The Pharma Engine

| Year | Revenue | YoY Growth | EPS (Diluted) | EPS Growth | |---|---|---|---|---| | 2021 | $78.74B | -4.7% | $7.81 | +41.7% | | 2022 | $79.99B | +1.6% | $6.73 | -13.8% | | 2023 | $85.16B | +6.5% | $13.72* | +103.9% | | 2024 | $88.82B | +4.3% | $5.79 | -57.8% | | 2025 | $94.19B | +6.1% | $11.03 | +90.5% |

*2023 EPS includes $21.8B in discontinued operations (Kenvue). Normalized EPS was approximately $5.80.

The earnings volatility looks extreme, but it is mostly accounting noise from the Kenvue spinoff. Strip that out and you see a company growing revenue at a steady 4-6% annually with EPS power of $10-$11 when the dust settles.

FY 2025 was the breakout year for the new J&J: $94.2 billion in revenue, $26.8 billion in net income, and $11.03 in diluted EPS. This is the company firing on all cylinders as a pure pharma-medtech play.

Margins tell the real story:

| Metric | FY 2025 | |---|---| | Gross Margin | 67.88% | | Operating Margin | 26.85% | | Net Profit Margin | 28.46% | | FCF Margin | 20.91% |

A 28% net margin is elite. For context, Coca-Cola runs at 27%. Pfizer is at 8%. J&J is a profit machine.

Graham Number Calculation

Let us apply the Graham Number formula:

Graham Number = √(22.5 × EPS × Book Value Per Share)

EPS (Diluted): $11.03
Book Value Per Share: $33.57

Graham Number = √(22.5 × $11.03 × $33.57)

Graham Number = √($8,330.52)

Graham Number = $91.27

At $239.63, Johnson & Johnson trades at 2.63x its Graham Number. That is a significant premium.

Why the Graham Number understates J&J's value:

The Graham Number was designed for asset-heavy industrial companies in the 1950s. J&J's book value of $33.57 per share is depressed by $75.6 billion in treasury stock from decades of buybacks. The company also carries $99.2 billion in intangible assets (goodwill and patents from acquisitions like Actelion) which Graham would have partially excluded.

For pharmaceutical companies, the real assets are patents and pipelines — things that do not show up well on the balance sheet. The Graham Number is a useful floor, but it dramatically undervalues pharma giants.

Graham Intrinsic Value Formula

The growth-based formula gives us a better picture:

V = EPS × (8.5 + 2g) × 4.4 / Y

Where:

EPS = $11.03
g = estimated 5-year growth rate (analyst consensus: ~7%)
Y = current AAA corporate bond yield (~5.0%)

V = $11.03 × (8.5 + 14) × 4.4 / 5.0

V = $11.03 × 22.5 × 0.88

V = $218.39

By the Graham formula, J&J's intrinsic value is roughly $218. At $239.63, the stock trades at a 10% premium to this estimate.

Using a more reasonable base P/E of 12x (appropriate for a healthcare blue-chip growing at 7%):

Adjusted V = $11.03 × (12 + 14) × 0.88 = $252.37

That puts fair value closer to $252, making the current price look reasonable — about a 5% discount to adjusted intrinsic value.

The 64-Year Dividend Streak: What It Means

Johnson & Johnson is one of only a handful of companies on the Dividend Kings List 2026 with 60+ years of consecutive dividend increases. The streak began in 1962 — the same year JFK stared down the Cuban Missile Crisis.

Current dividend profile:

| Metric | Value | |---|---| | Annual Dividend | $5.20 | | Quarterly Payment | $1.30 | | Yield | 2.12% | | Payout Ratio | 47.14% | | 5-Year Dividend Growth Rate | ~4.8% | | Dividend Growth (2024-2025) | 4.84% |

The payout ratio of 47% is the standout number here. J&J pays out less than half its earnings as dividends. Compare that to Coca-Cola at 68% or AT&T before its 2022 cut at 95%+.

A 47% payout ratio means J&J could nearly double its dividend and still not be in the danger zone. This is one of the safest dividends in the entire market.

Recent dividend history:

| Year | Annual Dividend | Growth | |---|---|---| | 2021 | $4.19 | +5.3% | | 2022 | $4.45 | +6.2% | | 2023 | $4.70 | +5.6% | | 2024 | $4.91 | +4.5% | | 2025 | $5.20 | +4.8% |

Steady 5% annual increases. Not spectacular. But 64 years of it compounding adds up to extraordinary wealth. If you invested $10,000 in J&J stock 30 years ago, you would be collecting over $4,000 per year in dividends today — a 40%+ yield on cost.

The Litigation Elephant: Talc and Beyond

No J&J analysis is complete without addressing the litigation overhang. The company has faced thousands of lawsuits alleging its talc-based baby powder caused cancer. J&J used a controversial legal strategy (the "Texas Two-Step" bankruptcy) to try to resolve these claims, offering $8.9 billion in settlements.

Where things stand in 2026:

The latest settlement plan received mixed court rulings
J&J has set aside billions in reserves
The company's strong cash position ($20.1B cash, $23.1B annual FCF) can absorb virtually any outcome
Management has signaled willingness to settle at levels that would not materially impair the business

The talc liability is real, but it is not existential. J&J generates enough free cash flow to pay a multi-billion dollar settlement and still fund its dividend, R&D, and acquisitions. At $239, some litigation risk is priced in — but probably not all of it.

The Bull Case for Johnson & Johnson

1. Pharma Pipeline Is Loaded J&J has 14+ drugs in Phase 3 trials. Darzalex (multiple myeloma) is growing 20%+ annually. Tremfya is expanding into new indications. The company spent $14.7 billion on R&D in 2025 — that investment feeds growth for the next decade.

2. Post-Kenvue Focus Without the low-margin consumer business dragging down results, J&J can allocate capital more efficiently. Higher margins, faster growth, and a cleaner investment thesis.

3. Fortress Balance Sheet $20.1 billion in cash, $23.1 billion in annual free cash flow, and a payout ratio under 50%. This company can fund growth, pay dividends, buy back stock, AND absorb litigation costs simultaneously.

4. 64-Year Dividend King The dividend streak is not just history — it is a commitment. J&J management knows cutting the dividend would destroy decades of institutional trust. The streak will continue.

5. Low Beta (0.33) J&J barely moves when the market crashes. During the 2022 bear market, J&J fell less than 5% while the S&P 500 dropped 20%. This is the ultimate sleep-at-night stock.

The Bear Case for Johnson & Johnson

1. Patent Cliffs Are Real Stelara (immunology blockbuster generating ~$21B annually at peak) faces biosimilar competition starting in 2025. While J&J is replacing it with Tremfya and other drugs, there will be a revenue gap.

2. Talc Liability Uncertainty The final talc settlement amount is still unknown. While J&J can afford it, a worst-case outcome (say, $15-20B+) would pressure the stock price.

3. Analyst Price Target Is BELOW Current Price The consensus analyst price target of $228.56 is 4.6% below the current price. Wall Street thinks J&J is slightly overvalued here. That is a yellow flag.

4. Revenue Concentration Risk Without the consumer segment, J&J is more dependent on a handful of blockbuster drugs. If pipeline replacements disappoint, growth stalls.

5. Modest Yield At 2.12%, J&J's yield is below the S&P 500 average. Income-focused investors can find higher yields elsewhere (see our Pfizer analysis at 6.46%).

Pros and Cons Summary

| Pros | Cons | |---|---| | 64-year dividend growth streak | Patent cliff risk (Stelara) | | 47% payout ratio — ultra-safe dividend | Talc litigation uncertainty | | 28% net profit margin | Analyst target below current price | | $23B+ annual free cash flow | Only 2.12% yield | | Beta of 0.33 — recession-proof | Revenue more concentrated post-Kenvue | | Loaded pharmaceutical pipeline | Premium to Graham intrinsic value |

Our Verdict: Buy on Pullback — Fair Value $215-$240

Johnson & Johnson is the definition of a quality compounder. The post-Kenvue J&J is actually a better company — higher margins, cleaner focus, and a pipeline that should replace Stelara's revenue over the next few years.

Our fair value range: $215-$240

$215 = Graham intrinsic value with conservative 7% growth
$240 = Adjusted intrinsic value accounting for pharma-appropriate P/E
Current price of $239.63 is at the top of our range

Our recommendation:

If you own JNJ: Hold. The 64-year streak is sacred. The payout ratio gives massive buffer. You have a compounder.
If you want to buy JNJ: The current price is at the top of fair value. Wait for a pullback to the $210-$225 range for a better entry. J&J pulled back to $141 in 2024 — patience pays.
Dollar-cost averaging: At $240, small position building is acceptable given the quality. Do not go all-in.

Rating: BUY on pullback (not at current levels)

Best for: Conservative investors seeking reliable dividend income, portfolio ballast, and recession protection. This is a 20-year hold.

Not for: Income seekers who need 4%+ yield or growth investors looking for double-digit returns.

How to Buy JNJ Stock

Ready to add Johnson & Johnson to your dividend portfolio?

Open a Moomoo Account — Get up to 15 free stocks when you deposit. Professional-grade tools for analyzing dividend stocks like JNJ.

Open a Webull Account — Commission-free stock trading with fractional shares. Start your J&J position with as little as $5.

Set up a DRIP and let J&J's 64-year dividend machine compound for you. The best time to start is now — the second best time is after a pullback.

Related Tools

Graham Number Calculator — Run the Graham Number for JNJ or any stock
Intrinsic Value Calculator — Calculate J&J's intrinsic value with the full Graham formula
Dividend Yield Calculator — Track JNJ's yield in real-time
DRIP Calculator — See what $10,000 in JNJ becomes with 20 years of DRIP

Disclaimer: This analysis is for educational purposes only and does not constitute financial advice. Always do your own research before making investment decisions. Data accurate as of March 2026.